Prestige Consumer Healthcare Files 8-K

Ticker: PBH · Form: 8-K · Filed: May 14, 2024 · CIK: 1295947

Prestige Consumer Healthcare Inc. 8-K Filing Summary
FieldDetail
CompanyPrestige Consumer Healthcare Inc. (PBH)
Form Type8-K
Filed DateMay 14, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.01, $300.0 million
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-reporting, company-update

TL;DR

PRESTIGE CONSUMER HEALTHCARE FILED AN 8-K ON MAY 14, 2024, WITH FINANCIAL UPDATES.

AI Summary

Prestige Consumer Healthcare Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition. The filing also included information regarding Regulation FD disclosure, other events, and financial statements and exhibits. The company, formerly known as Prestige Brands Holdings, Inc., is based in Tarrytown, NY.

Why It Matters

This 8-K filing provides investors with crucial updates on Prestige Consumer Healthcare's financial performance and other material events, impacting their investment decisions.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting financial information and other events, not indicating any immediate or significant new risks.

Key Players & Entities

  • Prestige Consumer Healthcare Inc. (company) — Registrant
  • May 14, 2024 (date) — Date of earliest event reported
  • Tarrytown, New York (location) — Principal Executive Offices
  • Prestige Brands Holdings, Inc. (company) — Former Company Name

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Prestige Consumer Healthcare Inc.'s results of operations and financial condition, as well as to disclose Regulation FD information, other events, and financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on May 14, 2024.

What is the principal executive office address for Prestige Consumer Healthcare Inc.?

The principal executive office address is 660 White Plains Road, Tarrytown, New York 10591.

What was the former name of Prestige Consumer Healthcare Inc.?

The former name of Prestige Consumer Healthcare Inc. was Prestige Brands Holdings, Inc.

What is the SIC code for Prestige Consumer Healthcare Inc.?

The Standard Industrial Classification (SIC) code for Prestige Consumer Healthcare Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 978 words · 4 min read · ~3 pages · Grade level 11.4 · Accepted 2024-05-14 17:04:38

Key Financial Figures

  • $0.01 — ich registered Common stock, par value $0.01 per share PBH New York Stock Exchange
  • $300.0 million — which the Company may repurchase up to $300.0 million of the Company's issued and outstanding

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On May 14, 2024, Prestige Consumer Healthcare Inc. (the "Company") announced financial results for the fiscal quarter and year ended March 31, 2024. A copy of the press release announcing the Company's earnings results for the fiscal quarter and year ended March 31, 2024 is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. The information set forth in Item 2.02 above is incorporated by reference as if fully set forth herein. On May 14, 2024, representatives of the Company began making presentations to investors regarding the Company's financial results for the quarter and year ended March 31, 2024 using slides containing the information attached to this Current Report on Form 8-K as Exhibit 99.2 (the "Investor Presentation"). The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others during the fiscal year ended March 31, 2024. By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission ("SEC") filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure. The information presented in Items 2.02 and 7.01 of this Current Report on Form 8-K and Exhibits 99.1 and 99.2 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered "filed" under the Exchange Act or specific

01 Other Events

Item 8.01 Other Events . On May 14, 2024, the Company also announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300.0 million of the Company's issued and outstanding common stock. The repurchases may occur in open market transactions, transactions structured through investment banking institutions, in privately-negotiated transactions, by direct purchases of common stock or a combination of the foregoing, and the timing and amount of stock repurchased will depend on market and business conditions, applicable legal and credit requirements and other corporate considerations. A copy of the press release announcing the share repurchase program is attached hereto as Exhibit 99.1, and solely that portion of the press release under the heading "Share Repurchase Program Authorization" is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. See Exhibit Index immediately following the signature page.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 14, 2024 PRESTIGE CONSUMER HEALTHCARE INC. By: /s/ Christine Sacco Name: Christine Sacco Title: Chief Financial Officer EXHIBIT INDEX Exhibit Description 99.1 Press Release dated May 14, 2024 announcing the Company's financial results for the fiscal quarter and year ended March 31, 2024 (furnished only) and the share repurchase program. 99.2 Investor Relations Slideshow in use beginning May 14, 2024 (furnished only). 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.